Want to join the conversation?
$REGN 2Q15 Call: Pivotal Phase 3 studies in the atopic dermatitis indication are fully enrolled and the company expects to report data from these studies in 1H16. Second pivotal study of Dupilumab in asthma is currently enrolling patients. This Phase 3 study will explore two doses of Dupilumab, 200 and 300 mg administered every other week.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!